Secoisolariciresinol

CAS No. 29388-59-8

Secoisolariciresinol( —— )

Catalog No. M24214 CAS No. 29388-59-8

Secoisolariciresinol is an enterolignan precursor, it has antioxidant, and estrogen-like activities, it can significantly suppress triglyceride (TG) accumulation in 3T3-L1 adipocytes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 288 In Stock
10MG 428 In Stock
25MG 701 In Stock
50MG 981 In Stock
100MG 1323 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Secoisolariciresinol
  • Note
    Research use only, not for human use.
  • Brief Description
    Secoisolariciresinol is an enterolignan precursor, it has antioxidant, and estrogen-like activities, it can significantly suppress triglyceride (TG) accumulation in 3T3-L1 adipocytes.
  • Description
    Secoisolariciresinol is an enterolignan precursor, it has antioxidant, and estrogen-like activities, it can significantly suppress triglyceride (TG) accumulation in 3T3-L1 adipocytes.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    TNF-α
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    29388-59-8
  • Formula Weight
    362.4
  • Molecular Formula
    C20H26O6
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    COC1=C(C=CC(=C1)C[C@@H](CO)[C@@H](CC2=CC(=C(C=C2)O)OC)CO)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.The Effect of Secoisolariciresinol on 3T3-L1 Adipocytes and the Relationship between Molecular Structure and Activity.Biosci Biotechnol Biochem. 2009 Jan;73(1):35-9.
molnova catalog
related products
  • Rehmannioside A

    Rehmannioside A is an iridoid glucoside extracted from traditional Chinese medicine Rehmannia.

  • Pomalidomide

    A potent inhibitor of TNF-α production; inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs.

  • Certolizumab pegol

    Certolizumab pegol (Certolizumab) is a polyethylene glycolated and humanized anti-TNF-α monoclonal antibody for the study of autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).